Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms

• Published in: British journal of haematology Vol. 202; no. 2; pp. 284 - 288
• Main Authors: Systchenko, Thomas, Chomel, Jean‐Claude, Gallego‐Hernanz, Pilar, Moya, Niels, Desmier, Déborah, Maillard, Natacha, Bobin, Arthur, Vonfeld, Mathilde, Gardeney, Hélène, Cayssials E, Emilie, Torregrosa, José
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.07.2023; Wiley
• Subjects: Aged; Aged, 80 and over; azacitidine; Azacitidine - adverse effects; Azacytidine; Blast Crisis - drug therapy; blast phase myeloproliferative neoplasms; Hematology; Human health and pathology; Humans; Life Sciences; Myeloproliferative Disorders - drug therapy; Quality of Life; Remission; ruxolitinib; Toxicity; Treatment Outcome; venetoclax; blast phase myeloproliferative neoplasms; ruxolitinib; venetoclax; azacitidine
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.18853

Summary Myeloproliferative neoplasms in blastic phase (MPN‐BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN‐BP patients treated with a never‐before‐described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed to control constitutional symptoms). Median age was 76 years (range 72–84), and worst performance status was 2. The overall response rate was 80%, and the complete remission rate was 40%. With median follow‐up of 10.0 months (range 4.2–13.4), median overall survival was 13.4 months (95% CI 4.2–13.4). We did not detect any unexpected treatment‐related toxicity, and quality of life was improved.